



International Union of Toxicology

**PROPOSAL TO THE NOMINATING COMMITTEE:
MEMBERS SUITABLE FOR NOMINATION TO THE IUTOX EXECUTIVE COMMITTEE
FOR THE PERIOD 2019-2022**


Proposal due to Barbara Hales at the [IUTOX Secretariat](#) by: **November 19, 2018**
Please include a short CV for the nominee

PROPOSAL SUBMITTED BY

Member Society: Society of Toxicology

Name and signature of IUTOX Member Society representative submitting nomination: Patricia E. Ganey

Position: SOT Past President/IUTOX Councilor

Signature: 

Date: October 22, 2018

BIOGRAPHICAL DETAILS OF PROPOSED CANDIDATE

Name and signature of proposed candidate: Dori R. Germolec



Nomination for officer or director may be indicated: IUTOX Director

Date of Birth: September 27, 1958

Current Position: Deputy Branch Chief, Toxicology Branch, Division of the National Toxicology Program, National Institute of Environmental Health Sciences

Address:

NIEHS/NIH
Toxicology Branch, DNTP
111 Alexander Dr
P O Box 12233
MD K2-15
Research Triangle Park, NC 27709

Nationality: US**Scientific Field:** Immunotoxicology**Education:**

North Carolina State University, PhD, Toxicology, 1995; Duke University, MA, Physical Anthropology, 1983; Duke University, BA, Anthropology, 1979.

Professional positions held (with dates):

Toxicologist, Immunology Discipline Leader, Toxicology Branch, National Toxicology Program, National Institute of Environmental Health Sciences (2005-present)

Adjunct Assistant Professor, Molecular Biomedical Sciences Dept, College of Veterinary Medicine, North Carolina State University (2004-Present)

Group Leader, Environmental Immunology Laboratory, National Institute of Environmental Health Sciences (1995-2005)

Biologist, Environmental Immunology Group, National Institute of Environmental Health Sciences (1985-1995)

IUTOX positions held (with dates):

10th Congress of Toxicology in Developing Countries, Scientific Program Committee, Belgrade, Serbia (2018)

International Congress of Toxicology XIV, Scientific Program Committee, Merida, Mexico (2016)

Member Society positions held (with dates):

ICTXV Continuing Education Committee Co-chair 2017-present; SOT Councilor 2011-2015; Education Committee, 2008–2014; Education Subcommittee: K–12 Task Force, Education Committee Liaison, 2009–2011; Program Committee, 2003–2006; North Carolina Regional Chapter, 2001–present; Women in Toxicology Special Interest Group, 2002–present; Clinical and Translational Toxicology Specialty Section 2015;

Dermal Toxicology Specialty Section, 2000–2014; Immunotoxicology Specialty Section, 1996–present, President, 2000–2001, Councilor, 1996–1998.

Professional memberships and/or awards:

Her scientific investigations have yielded more than 150 publications in various areas of toxicology, resulting in the receipt of two NIH Merit Awards and the Society of Toxicology Board of Publications Award in 1995. In 2017, Dr. Germolec received the Vos Award for Career Achievement in Immunotoxicology from the Immunotoxicology Specialty Section of the SOT. In 2004, she received the Outstanding Young Investigator Award from the SOT Immunotoxicology Specialty Section. The Immunotoxicology Specialty Section of the Society of Toxicology awarded Best Paper of the Year in 2010 to a paper that Dr. Germolec co-authored.

Other memberships:

NIEHS Assembly of Scientists, President 2011

NIEHS Assembly of Scientists, President-Elect 2010

NIEHS Assembly of Scientists, Secretary 2002-2009

NIEHS Assembly of Scientists, Councilor 2000-2001

President, Toxicology Graduate Student Association

North Carolina State University 1993 - 1994

Secretary-Treasurer, Toxicology Graduate Student Association North Carolina State University 1991 - 1992

DORI RABIN GERMOLEC

6 Willowspring Pl.
Chapel Hill, NC 27514
(919) 403-8282

EDUCATION

- Ph.D.** Toxicology, North Carolina State University 1995
Thesis: Induction of CYP1A1 and ALDH-3 in Immune Cells and Tissues in the Fisher 344 Rat
- M.A.** Physical Anthropology and Anatomy, Duke University 1983
Thesis: Food Choice From Endemic North Carolina Tree Species by Captive Prosimians (*Lemur fulvus*)
- B.A.** Physical Anthropology, Duke University 1979

BRIEF CHRONOLOGY OF EMPLOYMENT

Immunology Discipline Leader, Toxicologist, 2005- Present
Toxicology Branch, National Toxicology Program,
National Institute of Environmental Health Sciences

Serve as NTP project officer for R & D contracts in the area of immunotoxicology testing and methods development and for an interagency agreement with the National Institute of Occupational Safety and Health examining immunotoxicology in humans. Serve as discipline leader for immunology to the National Toxicology Program. Serve as lead toxicologist on NTP Toxicology studies investigating health effects following exposures to deoxynivalenol, mold, resveratrol and silica and participate in design teams to develop research programs for other NTP chemicals of interest. Serve as a subject matter expert on the effects of the microbiome in toxicology studies.

Group Leader, Environmental Immunology Laboratory, 1995 - 2005
National Institute of Environmental Health Sciences

Supervised a research laboratory of postdoctoral fellows, technicians, and students investigating the effects of environmental, industrial, and pharmacologic agents on the immune system. Research focus included both applied (development of methods and mathematical models to minimize uncertainties in risk assessment) and basic research (cellular and molecular roles of inflammatory cytokines in toxicity). Served as NTP project officer for R & D contracts in the area of immunotoxicology testing and methods development and for an interagency agreement with the National Institute of Occupational Safety and Health examining immunotoxicology in humans. Served as discipline leader

for immunology to the National Toxicology Program. Participated in the conduct and design of NTP Toxicology and Carcinogenicity studies.

Biologist, Environmental Immunology Group, 1985 - 1995
National Institute of Environmental Health Sciences

Conducted laboratory research into the cellular and molecular roles of cytokines in toxicity, studying a number of target organ systems, including the skin, lung, and liver. Examined the mechanisms by which environmental, industrial, and pharmacologic agents alter immune function and resistance to neoplasia and disease. Investigated the relationship between the induction of metabolic enzymes and toxicity in immune cell populations. Used immunotoxicologic data within mathematical formulae to develop mathematical models for use in the risk assessment process. Served as laboratory manager, responsible for day-to-day laboratory operations. Trained visiting scientists and postdoctoral fellows in laboratory techniques and procedures. Supervised work-study students and technicians.

Immunology Senior Research Technician, 1982 - 1985
Duke University Medical Center

Isolated and purified proteins for use in *in vivo* cancer therapies in humans and experimental animals. Performed animal injections, surgeries, and necropsies. Conducted a wide variety of standardized assays to assess immune function in mice.

MENTORING

Adjunct Appointments: Adjunct Assistant Professor 2004- Present
Molecular Biomedical Sciences Dept, College of Veterinary Medicine, North Carolina State University

Postdoctoral Fellows Directed:

2018-Present	AtLee Watson, Ph.D., IRTA Fellow Madelyn Huang, Ph.D. IRTA Fellow
2015- 2018	Kelly Shipkowski, Ph.D., IRTA Fellow
2012- 2016	Kristen Ryan, Ph.D., IRTA Fellow
2013- 2015	Brian Sayers, Ph.D., IRTA Fellow
2011- 2014	Sheetal Thakur, Ph.D., IRTA Fellow
2010- 2011	Sang-Hyun Kim, Ph.D., Visiting Fellow
2000- 2004	Kevin Trouba, Ph.D., IRTA Fellow
2002- 2004	Michelle Carey, IRA Fellow
1998-1999	Libia Vega Lloyo, Visiting Fellow

Clinical Fellows Directed:

1999- 2002 Jane Blood-Siegfried, Duke Univ School of Nursing

Graduate Committees:

1999- 2002 Dorinda Brockaway, North Carolina State University
2000-2004 Janine Ezendam, Utrecht University
2008-2012 Jenna Benson, University of Montana

TEACHING

Introduction to Immunology and Immunotoxicology 2016, 2017, 2018
Interdisciplinary Faculty of Toxicology, Texas A & M University
College Station, TX

Lecturer, Introduction to Immunotoxicology, 2004, 2006
Autoimmunity, Immunogenomics, North Carolina State University

Guest Lecturer, Immunology and Immunotoxicology, 1998, 2000, 2002
Introduction to Mammalian Toxicology, Duke University

Guest Lecturer, Immunology and Immunotoxicology 1996
Introduction to Pharmacology and Toxicology, Bowman Gray University

Guest Lecturer, Autoimmunity, Resistance to Disease and Neoplasia 1995
Immunotoxicology, North Carolina State University

AWARDS

Vos Award for Career Achievement in Immunotoxicology, Immunotoxicology 2017
Specialty Section, Society of Toxicology

NIH Merit Award 1999, 2009, 2013

Immunotoxicology Specialty Section, Best Paper of the Year 2010

NIEHS Unsung Hero Award 2008

Top Cited Papers 2005-2007 Award 2008
Free Radical Biology & Medicine, Elsevier Publishers

Outstanding Young Investigator Award, Immunotoxicology Specialty Section, Society of Toxicology	2004
Board of Publications Award, Best Paper in Fundamental and Applied Toxicology, Society of Toxicology	1995
Presentation Award, Immunotoxicology Specialty Section, Society of Toxicology	1995 and 1990
Student Travel Award, North Carolina Society of Toxicology	1995 and 1990
Special Service Award, National Institute of Environmental Health Sciences	1995
Student Presentation Award, Immunology Curriculum North Carolina State University	1994

ELECTED POSITIONS

Councilor, Society of Toxicology	2011-2014
Education Committee, Society of Toxicology	2008-2011
NIEHS Assembly of Scientists, President	2011
NIEHS Assembly of Scientists, President-Elect	2010
NIEHS Assembly of Scientists, Secretary	2002-2009
NIEHS Assembly of Scientists, Councilor	2000-2001
President, Immunotoxicology Specialty Section, Society of Toxicology	2000-2001
Councilor, Immunotoxicology Specialty Section, Society of Toxicology	1996- 1998
President, Toxicology Graduate Student Association North Carolina State University	1993 - 1994
Secretary-Treasurer, Toxicology Graduate Student Association North Carolina State University	1991 - 1992

WORKING GROUPS/SCIENTIFIC REVIEW PANEL MEMBER:

IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 122 – Isobutyl Nitrite, β -Picoline, and Some Acrylates World Health Organization Lyon, France	2018
Validation Management Team (VMT) meeting/Multi-Immuno Tox Assay Japanese Center for the Validation of Alternative Methods/ National Institute of Health Sciences (NIHS), Kobe, Japan	2016-Present
NIOSH-National Occupational Research Agenda Cross-Sector Council Immune, Infectious and Dermal Disease Prevention	2016-Present
BPA Immunotoxicity Working Group, Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids, European Food Safety Authority Oslo, Norway	2016
Immunotoxicology Working Group Peer Review Committee Skin Sensitization Working Group Peer Review Committee Interagency Coordinating Committee on Validation of Alternative Methods (ICCVAM)	2007-Present
HESI, Immunotoxicology Technical Committee	2012-Present
Chair, NTP Report on Carcinogens Information Group: Evaluation of Evaluation of Trichloroethylene-induced immune effects and their role in Its potential carcinogenicity	2012-2014
WHO Task Force/Expert Review Panel, IPCS – Harmonized Guidance on Immunotoxicity Risk Assessment (for Chemicals) WHO, Bilthoven, The Netherlands	2007-2013
NIOSH-Stakeholder Joint Workgroup on Skin Notations	2005-2009
EPA Risk Assessment Task Force Immunotoxicology Guidelines Working group	2004-2008
Developmental Immunotoxicology Review Panel Health and Environmental Sciences Institute, ILSI	2003
Respiratory Hypersensitivity Review Panel Health and Environmental Sciences Institute	2003
Agricultural Biotechnology Risk Analysis Task Group	2003-2007

WHO Task Force/Expert Review Panel, IPCS EHC Document – Scientific Principles and Methods for Assessment of Autoimmunity Associated with Exposure to Chemicals, WHO, Bilthoven, The Netherlands	2002-2007
EPA Working Group, Immune Effects of Phenol Exposure, OSWER, USEPA	2002
Protein Allergenicity, Health and Environmental Sciences Institute	2002
Immunity, Infection and Vaccine Working Group, National Children’s Study	2001-2005
Animal Models to Detect Allergenicity to Foods and Genetically Modified Products, Health Canada, Ottawa, Canada	2001
Arsenic Research Partnership, Technology Transfer Conference, Expert Review Panel	2001
Developmental Immunotoxicology and Risk Assessment, Health and Environmental Sciences Institute, ILSI	2001
Popliteal Lymph Node Assay Subcommittee, Health and Environmental Sciences Institute, ILSI, Washington, DC	2000-2004
Workshop on Health Effects of Chemicals in Developing and Adult Animals, USEPA, RTP, NC	1999
EMF In Vivo Hazard Evaluation Working Group, Immunotoxicology Section, NIEHS, Phoenix, AZ	1998
American Water Works Association Research Foundation Project Advisory Committee, Sodium Arsenite Studies in p53+/- mice RTP, NC	1997-1999
Immunotoxicology Working Group Peer Review Committee Interagency Coordinating Committee on Validation of Alternative Methods (ICCVAM), Washington, DC	1997-1999
Rapporteur / Expert Review Panel, IPCS EHC #212 Scientific Principles and Methods for Assessing Allergic Hypersensitization Associated with Exposure to Chemicals, WHO, Bilthoven, The Netherlands	1997

Health Effects of Silicone Breast Implants, Scientific Review Panel, Washington, DC	1997
Conference on Arsenic: Health Effects, Mechanisms of Action and Research Issues, National Cancer Institute, Hunt Valley, MD	1997
Expert Review Panel, Ad Hoc Working Group on Immunotoxicity Organization for Economic Cooperation and Development, RTP, NC	1996
Expert Review Panel, IPCS EHC #180 Scientific Principles and Methods for Assessing direct Immunotoxicity Associated with Exposure to Chemicals, WHO, Bilthoven, The Netherlands	1996
International Expert Review Panel, Arsenic in Drinking Water American Water Works Association Research Foundation, Association of California Water Agencies, Ellicott City, MD	1995
Ad hoc member, Immunotoxicology of AIDS Therapeutics Grant Review Panel National Institute of Allergy and Infectious Diseases, Washington, DC	1995

ORGANIZING COMMITTEE MEMBER

International Congress of Toxicology XV, Organizing Committee Co-Chair, Continuing Education Committee	2014-Present
10 th Congress of Toxicology in Developing Countries, Scientific Program Committee, Belgrade, Serbia	2018
International Congress of Toxicology XIV, Scientific Program Committee, Merida, Mexico	2016
Immunotoxicology in Food and Ingredient Safety Assessment: Approaches and Case Studies, SOT/FDA	2015
National Toxicology Program, Immunotoxicology Criteria Working Group, NTP, NIEHS	2008
National Toxicology Program, Mold Studies Information Group NTP, NIEHS	2007
National Toxicology Program Retreat NTP, NIEHS	2006

Immunotoxicogenomics Workshop EPA, NIEHS, ILSI	2005
Course Organizer, Evaluation of Immunomodulation in Safety, Assessment, Society of Toxicology	2003
Environmental Factors in Autoimmune Disease, NIH (NIEHS, NIAID, ORD, OWH), EPA, AARDA	2003
Meeting Chair, Assessment of the Allergenic Potential of Genetically Modified Foods, NIEHS, EPA, FDA	2001
Developmental Immunotoxicology Workshop NIEHS, NIOSH	2001
Occupational and Environmental Factors in Autoimmunity RIVM, WHO, NIEHS, NIOSH	2000
Linking Environmental Agents and Autoimmune Diseases, NIEHS, USEPA, NIH, AARDA, RTP, NC	1998
Epidemiology of Immunotoxicology RIVM, WHO, NIEHS, EPA, NIOSH	1997
SPECIAL ACTIVITIES	
Society of Toxicology, Eminent Toxicology Lectures Work Group	2014-2017
Associate Editor, Toxicology and Applied Pharmacology	2007-2010
Society of Toxicology National Program Committee	2003-2006
Editorial Board, Encyclopedic Reference of Immunotoxicology	2002-2005
Editorial Board, Environmental Health Perspectives	2004-Present
Editorial Board, Toxicological Sciences	2003-Present
Editorial Board, Toxicology and Applied Pharmacology	1997-2007
Editorial Board, Journal of Immunotoxicology	2003-2009

Regular reviewer for: Journal of Investigative Dermatology,
Carcinogenesis, Journal of Immunology, Chemical Research in
Toxicology, Journal of Toxicology and Environmental Health,
Toxicology

Grant Reviewer for NASA, Lunar Dust Toxicity Research Project	2007-2008
Grant Reviewer for UNC Center for Environmental Health and Susceptibility	2005-2007
Grant Reviewer for SWEHSC, University of Arizona	2004-2006
Project Proposal Reviewer for NIOSH, ATSDR	2004-2006

INVITED PRESENTATIONS:

“Immunotoxicology testing within the National Toxicology Program (NTP) Reflections on the Past, Present and Future”, European Society of Toxicology Brussels, Belgium	2018
“Subchronic Exposures to Fungal Spores Promotes Allergic Pulmonary Inflammation”, International Congress of Toxicology, Merida, Mexico	2016
“The NTP immunotoxicology testing program for evaluation of chemical effects on the immune system”, Society of Toxicologic Pathology Modular Course, Raleigh, NC	2015
“Introduction to Immunology and Immunotoxicology” SOT FDA Colloquia on Emerging Toxicological Science Challenges in Food and Ingredient Safety: Immunotoxicology in Food and Ingredient Safety assessment: Approaches and Case Studies, FDA, College Park, MD	2015
“From Research to Regulatory Science: Toxicology Careers in Government” Society of Toxicology Annual Meeting, Phoenix, Arizona	2014
“The NTP immunotoxicology testing program and risk assessment for chemical effects on the immune system”, North Carolina State University Toxicology Program Alumni Lecture, Raleigh, NC	2013
“Risk Assessment for the Immunotoxicity of Chemicals in the Environment” European Society of Toxicology Stockholm, Sweden	2012

<p>“Review of the NTP immunotoxicology testing program and current immunotoxicology testing strategies” HEIS workshop on Approaches and Best Practices for Assessment of Immunotoxicity for Environmental Chemicals Washington, DC</p>	<p>2012</p>
<p>“Immunotoxicology testing in the NTP” NIEHS iPartners Teleconference Research Triangle Park, NC</p>	<p>2012</p>
<p>“Evidence for the Immunotoxicity of perflourinated compounds” Society of Toxicologic Pathology Denver, Colorado</p>	<p>2011</p>
<p>“Evidence for the Immunotoxicity of perflourinated compounds” XII International Congress of Toxicology Barcelona, Spain</p>	<p>2010</p>
<p>“Does immunomodulation early in life increase disease risk in children and beyond?” Special Lecture for the 16th Annual Meeting of the Japanese Society of Immunotoxicology, Asahikawa, Japan</p>	<p>2009</p>
<p>“In vivo models to study nanoparticle-mediated immunotoxicity” Workshop - “Considerations in preclinical immunotoxicity assessment of engineered nanomaterials”, Frederick, MD</p>	<p>2008</p>
<p>“Evaluating Adverse Upstream Endpoints for Risk Assessment in Immunotoxicology: Case Study of Polychlorinated Biphenyls” Moving Upstream: A Workshop on Evaluating Adverse Upstream Endpoints for Improved Decision Making and Risk Assessment Berkeley, California</p>	<p>2007</p>
<p>“Histological examination of the lymphoid organs is a sufficiently reliable Predictor of immunotoxicity”, Immunotoxicology Summer School Lyon, France</p>	<p>2006</p>
<p>“Gene expression alterations in immune system pathways following Exposure to immunosuppressive chemicals” Living in a Chemical World, Collegium Ramizini International Conference Bologna, Italy</p>	<p>2005</p>

- “Phthalates and the Immune System: Overview and Public Health Perspective”, Toxicology Forum 31st Annual Summer Meeting
Aspen, Colorado 2005
- “The Accuracy of Extended Histopathology to Detect Immunotoxic Chemicals”, International Federation of Societies of Toxicologic Pathology,
Kobe, Japan 2004
- “Improving the Sensitivity and Predictivity of Current Testing Strategies for Immunotoxicity”, European Societies of Toxicology,
Florence, Italy 2003
- “Cell Signaling and Gene Expression in Keratinocytes Following Arsenic Exposure”, 2nd International Conference on Oxidative Stress –
Skin Biology and Medicine, Andros, Greece 2003
- “Human Health Risks Arising From Chemical Effects on the Immune System”
Primary Immunodeficiency Disorders: New Research and the Threat of Bioterrorism, Center for Children’s Health and the Environment, Mt Sinai School of Medicine, Washington, DC 2003
- “Sodium Arsenite-Induced Alterations in COX-2 and Stress-Related Gene Expression: Role in Epidermal Carcinogenesis
Center for Environmental Health Sciences, University of Montana 2003
- Altered Gene Expression in the Skin Following Arsenic Exposure
American/Japanese Conference on Arsenic in Medicine and Biology
Honolulu, HA 2002
- Exogenous Factors, Autoantibodies and Autoimmune Disease
6th Dresden Symposium on Autoantibodies, Dresden, Germany 2002
- Altered Gene Expression in Keratinocytes Following Arsenic Exposure
5th International Conference on Arsenic Exposure and Health
San Diego, CA 2002
- Altered Gene Expression in Keratinocytes Following Arsenic Exposure
Department of Environmental Toxicology, University of California at Davis
Davis, CA 2002
- Autoimmunity and Immunotoxicology
Lab Med 2001, American Association of Clinical Chemistry
Division of Animal Clinical Chemistry Annual Meeting, New York, NY 2001

Arsenite-Modulated Gene Expression and Metabolism: In vitro and In vivo Implications for Carcinogenesis, 3rd International Meeting on Molecular Mechanisms of Metal Toxicity and Carcinogenicity
Stintino, Italy 2001

Autoimmunity and Immunotoxicology
Society of Toxicologic Pathology
Pheonix, AZ 2000

The Role of Cytokines in Target-Organ Toxicity
PANWAT Regional Chapter, Society of Toxicology
Portland, OR 1999

Risk Assessment in Immunotoxicology
International Federation of Societies of Toxicological Pathology
Cambridge, UK 1998

NIEHS PROJECT OFFICER

Project Officer, Conducting Comprehensive Toxicologic Assessments
Interagency Agreement with NIOSH (Y1-ES9045-09) 2007-Present

Project Officer, Potential for Environmental and Therapeutic Agents
To Induce Immunotoxicity, Contract with Burleson Research
Technologies 2014- Present

Project Officer, Immunotoxicity of Workplace Xenobiotics
Interagency Agreement with NIOSH (Y1-ES0001-03) 1995-Present

Project Officer, Potential for Environmental and Therapeutic Agents
To Induce Immunotoxicity, Contract with Virginia
Commonwealth University (N01-ES-05454) 1995-2012

Project Officer, Immune Cell Depletion and Disease Resistance
Interagency Agreement with CDER, FDA (Y1-ES-9019-02) 1999-2002

NIEHS COMMITTEES

Animal Care and Use Committee
(Chair: 2004-2010) 1998-2010

National Toxicology Program, Project Review Committee	1996-2017
Committee on Promotions II (Currently serve as chair)	2018-2020 2014-2016 2002-2005
Laboratory Support Promotions Committee (COP III)	1996 - 2003
Subject Matter Expert (HBV, HCV, TCE), NIEHS Report on Carcinogens Review Group	2002-2003
Radiation Safety Committee,	1994 - 1997
EEO Promotions Committee	1994
Search Committees:	
CMB, Deputy Director	2016
CMB, Staff Veterinarian	2014
CMB Chief, Animal Program Director	2012
Clinical Director, Division of Intramural Research	2012
CMB Staff Veterinarian	2010
Scientific Director, Division of Intramural Research	2009 - 2011
High Throughput Screening Branch Chief	2008
National Toxicology Program, Associate Director	2007
LEP, Lab Chief	2006
LRB- Host Defense Tenure Track	2005
LPC – Senior Scientist in Toxicology	2003
EB - Environmental Epidemiologist, Tenure Track	2003
LPP - Tenure-Track Investigator	2003
Knockout Core Facility Director	2002
Staff Veterinarian	2001

PUBLICATIONS:

Peer-reviewed journal articles:

1. Glander, KE and DP Rabin. Food choice from endemic North Carolina tree species by captive prosimians (*Lemur fulvus*). 1983. *Amer. J. Primatol.* 5:221-229.
2. Luster, MI, AN Tucker, DR Germolec, MT Silver, PT Thomas, SJ Vore and JR Bucher. Immunotoxicity studies on mice exposed to methylisocyanate. 1986. *Toxicol. Appl. Pharmacol.* 86:140-144.
3. Luster, MI, DR Germolec, MF Ackermann, GR Burleson, CW Jameson and HT Hayes. Immunosuppression by ochratoxin A: Correlation of depressed NK cell activity and increased susceptibility to tumor challenge. 1987. *Cancer Res.* 47:2259-2263.
4. Tucker, AN, JR Bucher, DR Germolec, MT Silver, SJ Vore and MI Luster. Immunotoxicity studies on mice exposed to methylisocyanate. 1987. *Environ. Health Perspect.* 72:139-141.
5. Rosenthal, GJ, DR Germolec, KR Lamm, MF Ackermann and MI Luster. 1987. Comparative effects of methotrexate and the nonclassical antifolate trimetrexate on the murine immune system. *Int. J. Immunopharm.* 9:793-801.
6. Luster, MI, DR Germolec, MT Silver, GC Clark, G Wiegand and GJ Rosenthal. 1988. Selective effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin and corticosteroid on in vitro activation, proliferation, and differentiation of murine B Lymphocytes. *J. Immunol.* 140:928-935.
7. Rosenthal, GJ, GW Wiegand, DR Germolec and MI Luster. 1988. Suppression of B cell function by methotrexate and trimetrexate: Evidence for inhibition of purine biosynthesis as the primary mechanism of action. *J. Immunol.* 141:410-416.
8. Germolec, DR, RR Maronpot, MF Ackermann, SJ Vore, GJ Rosenthal and MI Luster. 1988. Lack of a relationship between immune function and chemical-induced hepatocarcinogenesis in B6C3F1 mice. *Cancer Immunol. Immunotherapy* 27:121-127.
9. Germolec, DR, GC Clark, JA Blank, G Wiegand and MI Luster. 1988. Events associated with inhibition of B cell maturation by phorbol diester. *Int. J. Immunopharm.* 10:953-965.

10. Danilowicz, RM, G Reed, DR Germolec, MI Luster, KB Tomer, JF Curtis, T Higuchi and TE Eling. 1989. 12S,19- and 12S,20-dihydroxyeicosanoids: novel 12S-hydroxy-5,8-cis-10-trans-14-cis-eicosatetraenoic acid metabolites formed by hydroxylation and reduction in murine lymphocytes. *Arch. Biochem. Biophys.* 271:72-83.
11. Germolec, DR, RSH Yang, MF Ackermann, GJ Rosenthal, GA Boorman, M Thompson, P Blair and MI Luster. 1989. Immune suppression in mice caused by drinking a mixture of groundwater contaminants. *Fundam. Appl. Toxicol.* 13:377-387.
12. Rosenthal, GJ, MM Fort, DR Germolec, MF Ackermann, KR Lamm and MI Luster. 1989. Arsenic inhalation induced alterations in immune function and host resistance consistent with alterations in T cell immunity. *Inhalation Toxicol.* 1:113-127.
13. Luster, MI, GJ Rosenthal, DR Germolec, KL White, BA Fuchs, MM Fort, JE Tomaszewski, MT Thompson, P Blair and AE Munson. 1989. Comparative effect of three antinucleosides (AZT, DDC, and DDA) used in AIDS therapy on immune and hematopoietic functions in mice. *Toxicol. Appl. Pharmacol.* 101:328-339.
14. Ackermann, MF, TA Gasiewicz, KR Lamm, DR Germolec and MI Luster. 1989. Inhibition of polymorphonuclear neutrophil function by 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Toxicol. Appl. Pharmacol.* 101:470-480.
15. Luster, MI, DR Germolec and GJ Rosenthal. 1990. Immunotoxicology: review of current status. *Ann. Allergy* 64:427-432.
16. Rosenthal, GJ, RP Stranahan, MM Fort, DR Germolec, MF Ackermann, P Blair, KJ Schwab and MI Luster. 1990. Immunomodulation by a recombinant human alpha interferon - Evidence for divergent effects on immune effector cell function. *Fundam. Appl. Toxicol.* 14:666-675.
17. Kim, JY, DR Germolec and MI Luster. 1990. Panax ginseng as a potential immunomodulator: Studies in mice. *Immunopharm. Immunotoxicol.* 12:257-276.
18. Tryphonas, H, MI Luster, G Schiffman, L-L Dawson, M Hodgen, DR Germolec, S Hayward, F Bryce, JKC Loo, F Mandy and DL Arnold. 1991. Effect of chronic exposure of PCB (Aroclor 1254) on specific and nonspecific immune parameters in the rhesus (*Macaca mulatta*) monkey. *Toxicol. Appl. Pharmacol.* 16:773-786.

19. Clark, GC, JA Blank, DR Germolec and MI Luster. 1991. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) stimulates protein phosphorylation and tyrosine kinase activity in B lymphocytes. *Mol. Pharmacol.* 39:495-501.
20. Holladay, SD, P Lindstrom, BL Blaylock, CE Comment, DR Germolec, RE Morrissey, JJ Heindel and MI Luster. 1991. Perinatal thymocyte antigen expression and postnatal immune development altered by gestational exposure to tetrachlorodibenzo-p-dioxin (TCDD). *Teratology* 44:385-393.
21. Tryphonas, H, MI Luster, KL White, M Erdos, GR Burleson, DR Germolec, M Hodgen, S Hayward and DL Arnold. 1991. Effects of PCB (Aroclor 1254) on non-specific immune related parameters in rhesus (*Macaca mulatta*) monkeys. *Int. J. Immunopharm.* 13:639-648, 1991.
22. Luster, MI, GJ Rosenthal, W Cao, MB Thompson, AE Munson, D Prejean, G Shopp, BA Fuchs, DR Germolec and JF Tomaszewski. 1991. Experimental studies of the hematologic and immune system toxicity of nucleoside derivatives used against HIV infection. *Int. J. Immunopharm.* 13(S1):99-107.
23. Sanders, VM, FE Powell-Oliver, GJ Rosenthal, DR Germolec and MI Luster. 1991. Immune-associated toxicities induced by in vivo and in vitro exposure to interferon-alpha alone or in combination with nucleoside analogs. *Int. J. Immunopharm.* 13(S1):109-115.
24. Luster, MI, SD Holladay, BL Blaylock, DR Germolec, GC Clark, CE Comment, JJ Heindel, and GJ Rosenthal. 1992. TCDD inhibits murine thymocyte and B lymphocyte maturation. *Chemosphere* 25:115-118.
25. Comment, CE, BL Blaylock, DR Germolec, PL Pollock, Y Kouchi, HW Brown, GJ Rosenthal and MI Luster. 1992. Thymocyte injury following in vitro chemical exposure: Potential mechanisms for thymic atrophy. *J. Pharmacol. Exp. Therap.* 262:1267-1273.
26. Kligerman, AD, R Chapin, GL Erexson, DR Germolec, P Kwanyuen and RSH Yang. 1993. Analyses of cytogenetic damage in rodents following exposure to simulated groundwater contaminated with pesticides and herbicides. *Mutation Res.* 300:125-134.
27. Pollock, PL, DR Germolec, CE Comment, GJ Rosenthal and MI Luster. 1994. Human lymphocyte engrafted SCID mice as a model for immunotoxicity assessment: Studies with cyclosporine A and TCDD. *Fundam. Appl. Toxicol.* 22:130-138.

28. Luster, MI, DR Germolec, T Yoshida, F Kayama and M Thompson. 1994. Endotoxin-induced cytokine gene expression and excretion in the liver. *Hepatology* 19: 480-488.
29. Rosenthal, GJ, DR Germolec, ME Blazka, E Corsini, P Simeonova, P Pollock, L-Y Kong, J Kwon and MI Luster. 1994. Asbestos stimulates IL-8 production from human lung epithelial cells. *J. Immunol.* 153:3237-3244.
30. Germolec, DR, NH Adams and MI Luster. 1995. A comparative assessment of metabolic enzyme levels in selected macrophage populations. *Biochem. Pharmacol.* 50:1495-1504.
31. Luster, MI, JL Wilmer, DR Germolec, J Spalding, T Yoshida, K Gaido, P Simeonova, FG Burleson and A Bruccoleri. 1995. Role of keratinocyte-derived cytokines in chemical toxicity. *Toxicol. Lett.* 82/83:471-476.
32. Germolec, DR, EC Henry, R Maronpot, J Foley, NH Adams, T Gasiewicz and MI Luster. 1996. Induction of CYP1A1 and ALDH-3 in lymphoid tissues from Fisher 344 rats exposed to 2,3,7,8-tetrachlorodibenzodioxin (TCDD). *Toxicol. Appl. Pharmacol.* 137:57-66.
33. Blazka, ME, KR Penneyacker, PP Simeonova, A Bruccoleri, DR Germolec and MI Luster. 1996. Acetaminophen-induced changes in hepatic AP-1 DNA binding activity in mice *Res. Comm. Mol. Pathol. and Pharmacol.* 92/3: 259-273.
34. Burleson, FG, PP Simeonova, DR Germolec and MI Luster. 1996. Dermatotoxic chemicals stimulate of c-jun and c-fos transcription and AP-1 binding in human keratinocytes. *Res. Comm. Mol. Pathol. and Pharmacol.* 93: 131-147.
35. Germolec, DR, T Yoshida, K Gaido, JL Wilmer, PP Simeonova, F Kayama, F Burleson, W Dong, R Lange and MI Luster. 1996. Arsenic-induced overexpression of growth factors in human keratinocytes *Toxicol. Appl. Pharmacol.* 141: 308-318.
36. Bruccoleri, A, R Gallucci, DR Germolec, P Blackshear and MI Luster. 1997. Induction of early-immediate genes by tumor necrosis factor α contributes to liver repair following chemical-induced hepatotoxicity. *Hepatology* 25: 133-141.
37. Bojes, HK, DR Germolec, P Simeonova, A Bruccoleri, R Schoonhoven, MI Luster and RG Thurman. 1997. Antibodies to tumor necrosis factor α prevent increases in cell replication in liver due to the potent peroxisome proliferator, WY-14,643. *Carcinogenesis* 18: 669-674.

38. Blazka, ME, DR Germolec, PP Simeonova, A Bruccoleri, KR Penneypacker and MI Luster. 1997. Acetaminophen-induced hepatotoxicity is associated with early changes in NF- κ B and NF-IL6 DNA binding activity. *J. Inflammation* 47:138-50.
39. Bojes, HK, Rose, ML, Keller, BJ, Germolec, DR, Simeonova, P, Luster, MI and RG Thurman. 1997. Mitogenic Actions of Peroxisome Proliferators: Involvement of Protein Kinase C and Tumor Necrosis Factor α . *Drug Metabolism Rev.* 29: 235-260.
40. Lange, RW, DR Germolec, JF Foley and MI Luster. 1998. Antioxidants attenuate anthralin induced skin inflammation in BALB/c mice: Role of specific proinflammatory cytokines. *J. Leukocyte Biol.* 64:170-176.
41. Germolec, DR, J Spalding, H-S Yu, GS Chen, PP Simeonova, A Bruccoleri, GA Boorman, JF Foley and MI Luster. 1998. Arsenic Enhancement of skin neoplasia by chronic stimulation of growth promoting cytokines. *Amer. J. Pathol.* 153:1775-1785.
42. Stachlewitz, RF, V Seabra, DR Germolec and RG Thurman. 1999. Glycine and uridine prevent D-Galactosamine hepatotoxicity in the rat: role of kupffer cells. *Hepatology* 29:737-745.
43. Rose, ML, I Roussyn, HK Bojes, DR Germolec, MI Luster and RG Thurman. 1999. Role of kupffer cells in peroxisome proliferator-induced hepatocyte proliferation. *Drug Metab. Rev.* 31: 87-116.
44. Styblo, M, LM Del Razo, L Vega, DR Germolec, EL LeCluyse, GA Hamilton, W Reed, C Wang, WR Cullen and DJ Thomas. 2000. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. *Arch Toxicol* 74: 289-299.
45. Glover, RE, DR Germolec, R Patterson, NJ Walker, GW Lucier and RP Mason. 2000. Endotoxin-induced nitric oxide production in 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)-treated Fisher rats: Detection of nitrosyl hemoproteins by EPR spectroscopy. *Chem Res Toxicol* 13: 1051-1055.
46. Vega, L., M. Styblo, R. Patterson, W. Cullen, C. Wang and DR Germolec. 2001. Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes *Toxicol Appl Pharmacol* 172: 225-32.

47. Rose, ML, DR Germolec, M Lin, H Tsukamoto, R Schoonhoven and RG Thurman. 2001. Gadolinium chloride-induced hepatocyte proliferation is prevented by antibodies to tumor necrosis factor alpha. *Toxicol Appl Pharmacol* 170: 39-45.
48. Trouba, KJ, K Geisenhoffer and DR Germolec. 2002. Effect of redox modulation on arsenite-induced cytotoxicity and stress-related gene expression in NHEK, HaCaT and HEL30 keratinocytes. *Environ Health Perspect* 110 S5:761-6.
49. Hamadeh, HK, KJ Trouba, RP Amin, CA Afshari and DR Germolec. 2002. Coordination of altered DNA Repair and Damage Pathways in arsenite-exposed keratinocytes. *Toxicol Sci* 69: 306-16.
50. Blood-Siegfried, J, A Nyska, H Lieder, M Joe, L Vega, R Patterson and DR Germolec. 2002. Synergistic effect of Influenza A virus on endotoxin-induced mortality in rat pups: a potential model for sudden infant death syndrome. *Pediatr Res.* 52: 481-90.
51. Detweiler, CD, LJ Deterding, KB Tomer, CF Chignell, DR Germolec and RP Mason. 2002. Immunological Identification of the Heart Myoglobin Radical Specifically Formed by Hydrogen Peroxide. *Free Rad Biol Med* 33: 364-369.
52. Patterson, R, R Stachlewitz and DR Germolec. 2003. Induction of Apoptosis by 2,3,7,8-Tetrachlorodibenzo-p-dioxin Following Endotoxin Exposure. *Toxicol Appl Pharmacol* 190: 120-34.
53. Carey, MA, DR Germolec, JA Bradbury, RA Gooch, MP Moorman, GP Flake, R Langenbach and DC Zeldin. 2003. Accentuated TH2 airway Response After Allergen Challenge in COX-1 -/- Mice. *Am J Respir Crit Care Med* 167:1509-15.
54. Germolec, DR, A Nyska, M Kashon, CF Kuper, C Portier, C Kommineni, KA Johnson and MI Luster. 2004. Extended Histopathology in Immunotoxicity Testing: Interlaboratory Validation studies. *Toxicol Sci* 78: 107-15.
55. Trouba, KJ and DR Germolec. 2004. Micromolar Concentrations of Sodium Arsenite Induce Cyclooxygenase-2 Expression and Stimulate p42/44 Mitogen-Activated Protein Kinase Phosphorylation in Normal Human Epidermal Keratinocytes *Toxicol Sci* 79:248-57.
56. Patterson, R, L Vega-Lloyo, K Trouba, C Bortner and DR Germolec. 2004. Arsenic-Induced Alterations in the Contact Hypersensitivity Response in Babl/c Mice. *Toxicol Appl Pharmacol* 198: 434-43.

57. Cooper, GS, SA Martin, MP Longnecker, DP Sandler and DR Germolec. 2004. Associations Between Plasma DDE Levels and Immunologic Measures in African-American Farmers in North Carolina. *Environ Hlth Perspect* 112: 1080-4.
58. Blood-Siegfried J, A Nyska, K Geisenhoffer, H Leider, C Moomaw, K Cobb, B Shelton, W Coombs and D Germolec. 2004. Alteration in regulation of inflammatory response to influenza a virus and endotoxin in suckling rat pups: a potential relationship to sudden infant death syndrome. *FEMS Immunol Med Microbiol.* 42: 85-93.
59. Germolec DR, M Kashon, A Nyska, CF Kuper, C Portier, C Kommineni, KA Johnson and MI Luster. 2004. The accuracy of extended histopathology to detect immunotoxic chemicals. *Toxicol Sci.* 82: 504-14.
60. Xie Y, KJ Trouba, J Liu, MP Waalkes and DR Germolec. 2004. Biokinetics and subchronic toxic effects of oral arsenite, arsenate, monomethylarsonic acid, and dimethylarsinic acid in v-Ha-ras transgenic (Tg.AC) mice. *Environ Health Perspect.* 112: 1255-1263.
61. Kadiiska MB, BC Gladen, DD Baird, DR Germolec, LB Graham, CE Parker, A Nyska, JT Wachsman, BN Ames, S Basu, N Brot, GA Fitzgerald, RA Floyd, M George, JW Heinecke, GE Hatch, K Hensley, JA Lawson, LJ Marnett, JD Morrow, DM Murray, J Plastaras, LJ Roberts II, J Rokach, MK Shigenaga, RS Sohal, J Sun, RR Tice, DH Van Thiel, D Wellner, PB Walter, KB Tomer, RP Mason, JC Barrett. 2005. Biomarkers of oxidative Stress study II: are oxidation products of lipids, proteins and DNA markers of CCL4 poisoning? *Free Radic Biol Med.* 38: 698-710.
62. Gentry PR, TR Covington, G Lawrence, T McDonald, ET Snow, D Germolec, G Moser, JW Yeager, HJ Clewell III. 2005. Comparison of tissue dosimetry in the mouse following chronic exposure to arsenic compounds. *J Toxicol Environ Health A.* 68: 329-51.
63. Carey, MA, JA Bradbury, JM Seubert, R Langenback, DC Zeldin, DR Germolec. 2005. Contrasting effects of cyclooxygenase-1 (COX-1) and Cox-2 deficiency on host response to influenza A viral infection. *J Immunol.* 175: 6878-84.
64. Weaver JL, Chapdelaine JM, Descotes J, Germolec D, Holsapple M, House R, Lebec H, Meade J, Pieters R, Hastings KL, Dean JH. 2005. Evaluation of a lymph node proliferation assay for its ability to detect pharmaceuticals with potential to cause immune-mediated drug reactions. *J Immunotoxicol.* 2:11-20.

65. Patterson RM, DR Germolec. 2006 Gene expression alterations in immune system pathways following exposure to immunosuppressive chemicals. *Ann N Y Acad Sci.*,1076:718-27.
66. Carey MA, Card JW, Bradbury JA, Moorman MP, Haykal-Coates N, Gavett SH, Graves JP, Walker VR, Flake GP, Voltz JW, Zhu D, Jacobs ER, Dakhama A, Larsen GL, Loader JE, Gelfand EW, Germolec DR, Korach KS, Zeldin DC. 2007. Spontaneous Airway Hyperresponsiveness in Estrogen Receptor- α -deficient Mice. *Am J Respir Crit Care Med*175: 126-35.
67. Valenzuela OL, Germolec DR, Boria-Aburto VH, Contreras-Ruiz J, Garcia-Vargas GG, Del Razo LM. 2007. Chronic arsenic exposure increases TGF α concentration in bladder urothelial cells of Mexican populations environmentally exposed to inorganic arsenic. *Toxicol Appl Pharmacol*, 222: 264-70.
68. Patterson RM, Noga E, Germolec DR. 2007. Lack of Evidence for Contact Sensitization by Pfisteria extract. *Environ Health Perspect*, 115: 1023-8.
69. Waalkes MP, Liu J, Germolec DR, Trempus CS, Cannon RE, Tokar EJ, Tennant RW, Ward JM, Diwan BA. 2008. Arsenic exposure in utero exacerbates skin cancer response in adulthood with contemporaneous distortion of tumor stem cell dynamics. *Cancer Res.* 68:8278-85.
70. Blood-Siegfried J, Rambaud C, Nyska A, Germolec DR. 2008. Evidence for infection, inflammation and shock in sudden infant death: parallels between a neonatal rat model of sudden death and infants who died of sudden infant death syndrome. *Innate Immun.* 14:145-52.
71. Carey MA, Bradbury JA, Reboloso YD , Graves JP, Zeldin DC, Germolec DR. 2010. Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection. *PLoS One.* Jul 15:e11610. PMID: 20657653
72. Frawley RP, White, KL Jr., Brown R, Musgrove D, Walker NJ, Germolec DR. 2011. Gene Expression Alterations in Immune System Pathways in the Thymus Following Exposure to Immunosuppressive Chemicals. *Environ Health Perspect.* 119:371-6. PMID: 21041162
73. Corsini E, Avogadro A, Galbiati V, dell'Agli M, Marinovich M, Galli CL, Germolec DR. 2011. In vitro evaluation of the immunotoxic potential of perfluorinated compounds (PFCs). *Toxicol Appl Pharmacol.* 250:108-16. PMID:21075133

74. Corsini E, Sangiovanni E, Avogadro A, Galbiati V, Viviani B, Marinovich M, Galli CL, Dell'agli M, Germolec DR. 2012. In vitro characterization of the immunotoxic potential of several perfluorinated compounds (PFCs). *Toxicol Appl Pharmacol.* 258:248-55. PMID: 22119708
75. Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, Cohn RD, Jusko TA, Walker NJ, Germolec DR, Whitt IZ, Crockett PW, Pauley BA, Chan JY, Ross SJ, Birnbaum LS, Zeldin DC, Miller FW. 2012. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. *Arthritis Rheum.* 2012 Jul;64(7):2319-27. PMID:22237992
76. Yildirim E, Carey MA, Card JW, Dietrich A, Flake GP, Bradbury JA, Reboloso Y, Germolec DR, Morgan DL, Zeldin DC, Birnbaumer L. 2012. Severely Blunted Allergen-Induced Pulmonary Th2-Cell Response in Type 1 Transient Receptor Potential Channel (TRPC1)-Deficient Mice. *Am J Physiol Lung Cell Mol Physiol.* 2012 Sep 15;303(6):L539-49. PMID: 22797250
77. Rooney AA, Luebke RW, Selgrade MK, Germolec DR. Immunotoxicology and its application in risk assessment. *EXS.* 2012;101:251-87. PMID: 22945572
78. Kim JM, Kosak JP, Kim JK, Kissling G, Germolec DR, Zeldin DC, Bradbury JA, Baek SJ, Eling TE. NAG-1/GDF15 transgenic mouse has less white adipose tissue and a reduced inflammatory response. *Mediators Inflamm.* 2013;2013:641851. PMID: 23737651
79. Thakur SA, Nyska A, White KL Jr, Smith MJ, Auttachoat W, Germolec DR. Immunomodulatory activity of orphan drug Elmiron® in female B6C3F1/N mice. *Food Chem Toxicol.* 2014 Jun;68:196-203. PMID: 24657363
80. Frawley R, DeVito M, Walker NJ, Birnbaum L, White K Jr, Smith M, Maynor T, Recio L, Germolec D. Relative potency for altered humoral immunity induced by polybrominated and polychlorinated dioxins/furans in female B6C3F1/N mice. *Toxicol Sci.* 2014 Jun;139(2):488-500. PMID: 24713691
81. Sayers BC, Walker NJ, Roycroft JH, Germolec DR, Baker GL, Clark ML, Hayden BK, DeFord H, Dill JA, Gupta A, Stout MD. Lung deposition and clearance of microparticle and nanoparticle C60 fullerene aggregates in B6C3F1 mice and Wistar Han rats following nose-only inhalation for 13 weeks. *Toxicology.* 2016 Jan 2;339:87-96. PMID: 26612504.

82. Sayers BC, Germolec DR, Walker NJ, Shipkowski KA, Stout MD, Cesta MF, Roycroft JH, White KL, Baker GL, Dill JA, Smith MJ. Respiratory toxicity and immunotoxicity evaluations of microparticle and nanoparticle C60 fullerene aggregates in mice and rats following nose-only inhalation for 13 weeks. *Nanotoxicology*. 2016 Sep 30;1-11. PMID: 27618498
83. Frawley RP, Smith M, Cesta MF, Hayes-Bouknight S, Blystone C, Kissling GE, Harris S, Germolec D. Immunotoxic and hepatotoxic effects of perfluoro-n-decanoic acid (PFDA) on female Harlan Sprague-Dawley rats and B6C3F1/N mice when administered by oral gavage for 28 days. *J Immunotoxicol*. 2018 Dec;15(1):41-52. PMID: 29514525
84. Shipkowski KA, Sheth CM, Smith MJ, Hooth MJ, White KL Jr, Germolec DR. Assessment of immunotoxicity in female Fischer 344/N and Sprague Dawley rats and female B6C3F1 mice exposed to hexavalent chromium via the drinking water. *J Immunotoxicol*. 2017 Dec;14(1):215-227. PMID: 29141474
85. Johnson-Weaver BT, McRitchie S, Mercier KA, Pathmasiri W, Sumner SJ, Chan C, Germolec D, Kulis M, Burks AW, Staats HF. Effect of endotoxin and alum adjuvant vaccine on peanut allergy. *J Allergy Clin Immunol*. 2018 Feb;141(2):791-794. PMID: 28927819

Peer-reviewed journal articles resulting from NTP Contract Activities or Interagency Agreements – post 1998

1. Karrow, NA, JA McKay, RD Brown, DL Musgrove, DA Petit, AE Munson, DR Germolec and KL White, Jr. 2000. Thalidomide stimulates splenic IgM antibody responses and cytotoxic T lymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice. *Toxicol Appl Pharmacol* 165: 237-44.
2. Guo, TL, JA McKay, RD Brown, DL Musgrove, L Butterworth, AE Munson, DR Germolec and KL White, Jr. 2000. Glycidol modulation of the immune responses in female B6C3F1 mice. *Drug Chem Toxicol* 23: 433-57.
3. Guo, TL, JA McKay, RD Brown, DL Musgrove, DR Germolec, L Butterworth, AE Munson and KL White, Jr. 2000. Carbon tetrachloride is immunosuppressive and decreases host resistance to *Listeria monocytogenes* and *Streptococcus pneumoniae* in female B6C3F1 mice. *Toxicology* 154: 85-101.

4. Karrow, NA, JA McKay, RD Brown, DL Musgrove, DR Germolec and KL White, Jr. 2001. Evaluation of the immunomodulatory effects of the macrolide antibiotic, clarithromycin, in female B6C3F1 mice: a 28-day oral gavage study. *Drug Chem Toxicol* 24: 19-37.
5. Karrow, NA, EK Leffel, TL Guo, LX Zhang, JA McKay, DR Germolec, and KL White, Jr. 2001. Dermal exposure to cinnamaldehyde alters lymphocyte subpopulations, number of interferon-gamma-producing cells, and expression of B7 costimulatory molecules and cytokine messenger RNAs in auricular lymph nodes of B6C3F1 mice. *Am J Contact Dermat.* 12: 6-17.
6. Guo, TL, JA McKay, NA Karrow, RD Brown, DL Musgrove, RW Luebke, DR Germolec and KL White, Jr. 2001 Immunotoxicity of sodium bromate in female B6C3F1 mice: a 28-day drinking water study. *Drug Chem Toxicol* 24: 129-49.
7. Karrow, NA, TL Guo, JA McKay, GW Johnson, RD Brown, DL Musgrove, DR Germolec, RW Luebke and KL White, Jr. 2001. Evaluation of the immunomodulatory effects of the disinfection by-product, sodium chlorite, in female B6C3F1 mice: a drinking water study. *Drug Chem Toxicol* 24: 239-58.
8. Guo, TL, JA McKay, LX Zhang, RD Brown, L You, NA Karrow, DR Germolec and KL White, Jr. 2001. Genistein modulates immune responses and increases host resistance to B16F10 tumors in adult female B6C3F1 mice. *J Nutr* 131: 3251-8.
9. Weaver, JL, DD Broudy, K McKinnon and DR Germolec. 2002. Serial Phenotypic Analysis of Mouse Peripheral Blood Leukocytes. *Toxicol Mechanisms and Methods* 12: 95-118.
10. Guo, TL, XL Zhang, EK Leffel, VL Peachee, NA Karrow, DR Germolec and KL White, Jr.. 2002. Differential Stimulation of IgE Production, STAT Activation, and Cytokine and CD86 Expression by 2,4,-Dinitrochlorobenzene and Trimellitic Anhydride. *J Appl Toxicol* 22: 397-403.
11. Guo, TL, KL White, Jr., RD Brown, KB Delclos, RR Newbold, C Weis, DR Germolec, and JA McKay. 2002. Genistein Modulates Splenic Natural Killer Cell Activity, Antibody-forming Cell Responses and Phenotypic marker Expression in F0 and F1 Generations of Sprague Dawley Rats. *Toxicol Appl Pharmacol* 181: 219-27.
12. Karrow, NA, TL Guo, EK Leffel, LX Zhang, JA McKay, DR Germolec and KL White, Jr. 2002. Sodium Metasilicate Hypersensitivity in BALB/C Mice. *Am J Contact Dermat* 13: 133-9.

13. Karrow, NA, TL Guo, LX Zhang, JA McCay, DL Musgrove, VL Peachee, DR Germolec, KL White, Jr. 2003. Thalidomide modulation of the immune response in female B6C3F1 mice: a host resistance study. *Int Immunopharmacol.* 3:1447-56.
14. He, B., S Rhodes-Brower, MR Miller, AE Munson, DR Germolec, VR Walker, KS Korach and BJ Meade. 2003. Octamethylcyclotetrasiloxane exhibits estrogenic activity in mice via ER α . *Toxicol. Appl. Pharmacol* 192: 254-61.
15. Karrow, NA, TL Guo, KB Delclos, RR Newbold, C Weis, DR Germolec, KL White, Jr and JA McKay. 2004. Nonylphenol Alters the Activity of Splenic NK Cells and the Numbers of Leukocyte Subpopulations in Sprague-Dawley Rats: A Two Generation Feeding Study. *Toxicology* 196: 237-45.
16. White, KL, Jr, DR Germolec, DL Musgrove, KB Delclos, RR Newbold, C Weis and TL Guo. 2004. Vinclozolin Modulates Splenic Natural Killer Cell Activity, Antibody-Forming Cell Response and Phenotypic Marker Expression in Sprague-Dawley Rats: A Two-Generation Feeding Study. *J Immunotoxicol.* 1:113-121.
17. White, KL, Jr, DR Germolec, CD Booker, DM Hernandez, JA McKay, KB Delclos, RR Newbold C Weis, TL Guo. 2005. Dietary methoxychlor exposure modulates splenic natural killer cell activity, antibody-forming cell response and phenotypic marker expression in F0 and F1 generations of Sprague Dawley rats. *Toxicology.* 207: 271-81.
18. Karrow, NA, JA McKay, RD Brown, DL Musgrove, TL Guo, DR Germolec, KL White, Jr. 2005. Oral exposure to atrazine modulates cell-mediated immune function and decreases host resistance to the B16F10 tumor model in female B6C3F1 mice. *Toxicology.* 209: 15-28.
19. Guo, TL, RP Chi, NA Karrow, LX Zhang, SB Pruet, DR Germolec, KL White, Jr. 2005. Thalidomide enhances both primary and secondary host resistance to *Listeria monocytogenes* infection by a neutrophil-related mechanism in female B6C3F1 mice. *Toxicol Appl Pharmacol.* 209: 244-54.
20. Guo TL, DR Germolec, DL Musgrove, KB Delclos, RR Newbold, C Weis, KL White, Jr. 2005. Myelotoxicity in genistein-, nonylphenol-, methoxychlor-, vinclozolin- or ethinyl estradiol-exposed F1 generations of Sprague-Dawley rats following developmental and adult exposures. *Toxicology.* 211: 207-19.
21. Guo TL, RP Chi, DR Germolec, KL White, Jr. 2005. Stimulation of the immune response in B6C3F1 mice by genistein is affected by exposure duration, gender, and litter order. *J Nutr.* 135: 2449-56.

22. Prater MR, VJ Johnson, DR Germolec, MI Luster, SD Holladay. 2006. Maternal treatment with a high dose of CpG ODN during gestation alters fetal craniofacial and distal limb development in C57BL/6 mice. *Vaccine* 24: 263-71.
23. Guo TL, RP Chi, XL Zhang, DL Musgrove, C Weis, DR Germolec, KL White, Jr. 2006. Modulation of immune response following dietary genistein exposure in F(0) and F(1) generations of C57BL/6 mice: Evidence of thymic regulation. *Food Chem Toxicol.* 44: 316-25.
24. Demchuk E, Yucesoy B, Johnson VJ, Andrew M, Weston A, Germolec DR, De Rosa CT, Luster MI. 2007. A statistical model for assessing genetic susceptibility as a risk factor in multifactorial disease from occupational asthma. *Environ Health Perspect* 115: 231-4.
25. Yucesoy B Johnson VJ, Kissling G, Fluharty K, Kashon M, Slaven J, Germolec D, Vallyathan V, Luster MI. 2008. Genetic Susceptibility to Progressive Massive Fibrosis in Coal Miners. *Eur Respir J.* 31:1177-82.
26. Auttachoat W, Germolec DR, Collins BJ, Luebke RW, White KL Jr, Guo TL. 2009. Immunotoxicological profile of chloroform in female B6C3F1 mice when administered in drinking water. *Drug Chem Toxicol.* 32:77-87. PMID: 19514942
27. Yucesoy B, Johnson VJ, Fluharty K, Kashon ML, Slaven JE, Wilson NW, Weissman DN, Biagini RE, Germolec DR, Luster MI. 2009. Influence of cytokine gene variations on immunization to childhood vaccines. *Vaccine.* 27:6991-7. PMID:19819209
28. Anderson SE, Munson AE, Butterworth LF, Germolec D, Morgan DL, Roycroft JA, Dill J, Meade BJ. 2010. Whole-body inhalation exposure to 1-bromopropane suppresses the IgM response to sheep red blood cells in female B6C3F1 mice and Fisher 344/N rats. *Inhal Toxicol.* 22:125-32. PMID: 20041805
29. Guo TL, Germolec DR, Roesh DM, White KL Jr. 2010. Immunomodulation in female B6C3F1 mice following treatment with the HIV protease inhibitor saquinavir for 28 days by gavage. *J Immunotoxicol.* 2010 Oct-Dec;7(4):289-97. PMID: 20560775
30. Smith MJ, Germolec DR, Luebke RW, Sheth CM, Auttachoat W, Guo TL, White KL Jr. 2010. Immunotoxicity of dibromoacetic acid administered via drinking water to female B6C3F1 mice. *J Immunotoxicol.* 7:333-43. PMID:20958156

31. Auttachoat W, Germolec DR, Smith MJ, White KL Jr, Guo TL. 2011. Contact sensitizing potential of annatto extract and its two primary color components, cis-bixin and norbixin, in female BALB/c mice. *Food Chem Toxicol.* 49:2638-44. PMID: 21777644
32. Guo TL, Germolec DR, Collins BJ, Luebke RW, Auttachoat W, Smith MJ, White KL. 2011. Immunotoxicological profile of chloramine in female B6C3F1 mice when administered in the drinking water for 28 days. *J Immunotoxicol.* 8:381-8. PMID: 22017662
33. Yucesoy B, Johnson VJ, Lummus ZL, Kissling GE, Fluharty K, Gautrin D, Malo J-L, Cartier A, Sastre J, Quirce S, Germolec DR, Boulet L-P, Tarlo SM, Cruz M-J, Munoz X, Luster MI, Bernstein DI. 2012. Genetic variants in antioxidant genes are associated with diisocyanate-induced asthma. *Toxicol Sci.* 2012 Sep;129(1):166-73. PMID:22610343
34. Endres SM, Green BJ, Henneberger PK, Germolec DR, Bledsoe TA, Beezhold DH, London SJ, Alavanja MC, Beane Freeman LE, Hoppin JA. Fungal and atopic sensitization are low among farmers in the Agricultural Health Study. *J Allergy Clin Immunol.* 2012 Jul;130(1):267-70. PMID: 22633325
35. Bernstein DI, Kashon M, Lummus ZL, Johnson VJ, Fluharty K, Gautrin D, Malo JL, Cartier A, Boulet LP, Sastre J, Quirce S, Germolec D, Tarlo SM, Cruz MJ, Munoz X, Luster MI, Yucesoy B. CTNNA3 (α -catenin) gene variants are associated with diisocyanate asthma: a replication study in a Caucasian worker population. *Toxicol Sci.* 2013 Jan;131(1):242-6. PMID: 22977168
36. Smith MJ, Germolec DR, Frawley RP, White KL Jr. Immunomodulatory effects of black cohosh (*Actaea racemosa*) extract in female B6C3F1/N mice. *Toxicology.* 2013 Jun 7;308:146-57. PMID: 23571075
37. Mathews JM, Watson SL, Patel PR, Black SR, Hong Y, Levine KE, Ross G, Germolec DR, Thakur SA, Waidyanatha S. Metabolism and disposition of [(14)C]dimethylamine borane in male Harlan Sprague Dawley rats following gavage administration, intravenous administration and dermal application. *Xenobiotica.* 2014 Jan;44(1):36-47. PMID: 23786350
38. Yucesoy B, Talzhanov Y, Johnson VJ, Wilson NW, Biagini RE, Wang W, Frye B, Weissman DN, Germolec DR, Luster MI, Barmada MM. Genetic variants within the MHC region are associated with immune responsiveness to childhood vaccinations. *Vaccine.* 2013 Nov 4;31(46):5381-91. PMID: 24075919

39. Guo TL, Germolec DR, Zhang LX, Auttachoat W, Smith MJ, White KL Jr. Contact sensitizing potential of pyrogallol and 5-amino-o-cresol in female BALB/c mice. *Toxicology*. 2013 Dec 15;314(2-3):202-8. PMID: 24172597
40. Yucesoy B, Johnson VJ, Lummus ZL, Kashon ML, Rao M, Bannerman-Thompson H, Frye B, Wang W, Gautrin D, Cartier A, Boulet LP, Sastre J, Quirce S, Tarlo SM, Germolec DR, Luster MI, Bernstein DI. Genetic variants in the major histocompatibility complex class I and class II genes are associated with diisocyanate-induced Asthma. *J Occup Environ Med*. 2014 Apr;56(4):382-7. PMID: 24709764
41. Buskirk AD, Green BJ, Lemons AR, Nayak AP, Goldsmith WT, Kashon ML, Anderson SE, Hettick JM, Templeton SP, Germolec DR, Beezhold DH. A murine inhalation model to characterize pulmonary exposure to dry *Aspergillus fumigatus* conidia. *PLoS One*. 2014. Oct 23;9(10):e109855. PMID: 25340353.
42. Guo TL, Germolec DR, Zheng JF, Kooistra L, Auttachoat W, Smith MJ, White KL, Elmore SA. Genistein Protects Female Nonobese Diabetic Mice from Developing Type 1 Diabetes When Fed a Soy- and Alfalfa-free Diet. *Toxicol Pathol*. 2015 Apr 43(3):435-48. PMID: 24713318.
43. Nayak AP, Green BJ, Lemons AR, Marshall NB, Goldsmith WT, Kashon ML, Anderson SE, Germolec DR, Beezhold DH. Subchronic exposures to fungal bioaerosols promotes allergic pulmonary inflammation in naïve mice. *Clin Exp Allergy*. 2016 Jun;46(6):861-70. Epub 2016 May 3. PMID: 26892490.
44. Yucesoy B, Talzhanov Y, Barmada MM, Johnson VJ, Kashon ML, Baron E, Wilson NW, Frye B, Wang W, Fluharty K, Gharib R, Meade J, Germolec D, Luster MI, Nedorost S. Genetic Basis of Irritant Susceptibility in Health Care Workers. *J Occup Environ Med*. 2016 May 18. [Epub ahead of print]. PMID: 27206134
45. Frawley RP, Smith MJ, White KL Jr, Elmore SA, Herbert R, Moore R, Staska LM, Behl M, Hooth MJ, Kissling GE, Germolec DR. Immunotoxic effects of sodium tungstate dihydrate on female B6C3F1/N mice when administered in drinking water. *J Immunotoxicol*. 2016 May 25:1-10. [Epub ahead of print] PMID: 27223060.
46. Yucesoy B, Talzhanov Y, Michael Barmada M, Johnson VJ, Kashon ML, Baron E, Wilson NW, Frye B, Wang W, Fluharty K, Gharib R, Meade J, Germolec D, Luster MI, Nedorost S. Association of MHC region SNPs with irritant susceptibility in healthcare workers. *J Immunotoxicol*. 2016 Jun 3:1-7. [Epub ahead of print]. PMID: 27258892.

47. Croston TL, Nayak AP, Lemons AR, Goldsmith WT, Gu JK, Germolec DR, Beezhold DH, Green BJ. Influence of *Aspergillus fumigatus* conidia viability on murine pulmonary microRNA and mRNA expression following subchronic inhalation exposure. *Clin Exp Allergy*. 2016 Oct;46(10):1315-27. PMID:27473664
48. Johnson VJ, Auerbach SS, Luster MI, Waidyanatha S, Masten SA, Wolfe MS, Burleson FG, Burleson GR, Germolec DR. Evaluation of 4-methylcyclohexanemethanol (MCHM) in a combined irritancy and Local Lymph Node Assay (LLNA) in mice. *Food Chem Toxicol*. 2017 Jul;105:99-105. doi: 10.1016/j.fct.2017.03.034. Epub 2017 Mar 22. PMID: 28343035
49. Nayak AP, Croston TL, Lemons AR, Goldsmith WT, Marshall NB, Kashon ML, Germolec DR, Beezhold DH, Green BJ. *Aspergillus fumigatus* viability drives allergic responses to inhaled conidia. *Ann Allergy Asthma Immunol*. 2018 Apr 13. pii: S1081-1206(18)30294-1. PMID: 29660515

Reviews and Conference Proceedings:

1. Luster, MI, AE Munson, PT Thomas, MP Holsapple, JD Fentners, KL White, LD Lauer, DR Germolec, GJ Rosenthal and JH Dean. 1988. Development of a testing battery to assess chemical-induced immunotoxicity: National Toxicology Program's guideline for immunotoxicity evaluation in mice. *Fundam. Appl. Toxicol*. 10:2-19.
2. Luster, MI, MF Ackermann, DR Germolec and GJ Rosenthal. 1989. Perturbations of the immune system by xenobiotics. In: *Proceedings from the 40th Symposium of the Institute of Environmental Medicine*. New York University Medical Center. *Environ. Health Perspect*. 81:157-162.
3. Luster, MI, DG Pait, C Portier, GJ Rosenthal, DR Germolec, CE Comment, AE Munson, KL White and PL Pollock. 1992. Qualitative and quantitative experimental models to aid in risk assessment for immunotoxicology. *Toxicol. Lett*. 64/65:71-78.
4. Luster, MI, C Portier, P Simeonova, D Germolec and AE Munson. 1996. Relationships between chemical-induced immunotoxicity and carcinogenesis. *Drug Info. J*. 30:281-286.

5. Luster, MI, C Portier, DG Pait, GJ Rosenthal, DR Germolec, E Corsini, BL Blaylock, PL Pollock, Y Kouchi, WA Craig, KL White, AE Munson and CE Comment. 1993. Risk assessment in immunotoxicology II: Relationships between immune and host resistance tests. *Fundam. Appl. Toxicol.* 21:71-82.
6. Germolec, DR and MI Luster. 1994. Hypersensitivity and occupational exposure. *EOS Rivista di Immunologia ed Immunofarmacologia* 14:107-113.
7. Luster, MI, C Portier, DG Pait and DR Germolec. 1994. The use of animal tests in risk assessment for immunotoxicology. *Toxicology In Vitro* 8(5):945-950.
8. Luster, MI, C Portier, DG Pait and DR Germolec. 1994 Use of animal studies in risk assessment for immunotoxicology. *Toxicology* 92:229-243.
9. Van Loveren, H, DR Germolec, HS Koren, MI Luster, C Nolan, R Repetto, E Smith, JG Vos and RF Vogt. 1999. Report of the Bilthoven Symposium: Advancement of epidemiological studies in assessing the human health effects of immunotoxic agents in the environment and the workplace. *Biomarkers* 4:135-157.
10. Styblo M, L Vega, DR Germolec, MI Luster, LM Del Razo, C Wang, WR Cullen, and DJ Thomas. 1999. Metabolism and toxicity of arsenicals in cultured cells. In: *Arsenic Exposure and Health Effects, Proceedings of the Third International Conference on Arsenic Exposure and Health Effects, July 12-15, 1998, San Diego, California* (WR Chappell, CO Abernathy and RL Calderon eds.) Elsevier Science Ltd, Oxford, England, pp 311-324.
11. Cooper, GC, D Germolec, J Heindel, and M Selgrade. 1999. Linking environmental agents and autoimmune diseases. *Environ Hlth Perspect.* 107 S5: 659-60.
12. Smith, DA and DR Germolec. 1999. Introduction to Immunology and Autoimmunity. *Environ. Health Perspect* 107S: 661-665.
13. Selgrade, MK, GS Cooper, DR Germolec and JJ Heindel. 1999. Linking environmental agents and autoimmune disease: an agenda for future research. *Environ Hlth Perspect.* 107 S5: 811-3.
14. Germolec, DR, MR Woolheiser, and BJ Meade. 1999. Allergy to Natural Rubber Latex. *Chemical Health and Safety* 6: 44-48.
15. Toraason M, G Sussman, R Biagini, BJ Meade, D Beezhold and D Germolec. 2000. Latex Allergy in the workplace. *Toxicol Sci* 58:5-14.

16. Van Loveren, H, JG Vos, D Germolec, PP Simeonova, G Eijkemanns and AJ McMichael. 2001. Epidemiologic associations between occupational and environmental exposures and autoimmune disease: report of a meeting to explore current evidence and identify research needs. *Int J Hyg Environ Health* 203: 483-95.
17. Rosenthal, GJ and Germolec, DR. 2001. Toxicology of the Immune System. In: *Toxicology Testing Handbook: Principles, Applications and Data Interpretation*, D Jacobson-Kram and Kit Keller (eds.), Marcel Dekker, Inc., NY, NY, pp 291-314.
18. Cooper, GS, FW Miller and DR Germolec. 2002. Occupational exposures and autoimmune diseases. *Int Immunopharmacol* 2: 303-313.
19. Trouba, KJ, HK Hamadeh, RP Amin and DR Germolec. 2002. Oxidative Stress and its Role in Skin Disease. *Antioxidants and Redox Signaling* 4: 665-73.
20. Geisenhoffer, K and DR Germolec. 2002. The role of exogenous factors in the induction of autoantibodies. In: *Report on the 6th Dresden symposium on Autoantibodies, September 4-7, 2002* (K. Conrad, M. Fritzler, M. Meurer, U. Sack and Y. Shoenfeld eds.) Pabst Science Publications, Lengerich, Germany, pp604-615.
21. Luster, MI, JH Dean and DR Germolec. 2003. Meeting Report: Consensus Workshop on Methods to Evaluate Developmental Immunotoxicity. *Environ Health Perspect* 111:579-583.
22. Selgrade, M, I Kimber, L Goldman and D Germolec. 2003. Assessment of the Allergenic Potential of Genetically Modified Foods: An Agenda For Future Research. *Environ Health Perspect* 111:1140-1.
23. Germolec, D, I Kimber, L Goldman and M Selgrade. 2003. Key Issues for the Assessment of the Allergenic Potential of Genetically Modified Foods: Breakout Group Reports. *Environ Health Perspect* 111:1131-9.
24. Trouba, K, A Nyska, M Styblo, D Dunson, L Lomnitski, S Grossman, G Moser, A Suttie, R Patterson, F Walton and D Germolec. 2003. Effect of Antioxidants on the Papilloma Response and Liver Glutathione Modulation Mediated by Arsenic in Tg.AC Transgenic Mice. In: *Arsenic Exposure and Health Effects V Proceedings of the Fifth International Conference on Arsenic Exposure and Health Effects, July 14-18, 2002, San Diego, California* (WR Chappell, CO Abernathy, RL Calderon and DJ Thomas eds.) Elsevier Science Ltd, Oxford, England, pp 283-293.

25. Carey, MA, DR Germolec, R Langenbach and DC Zeldin. 2003. Cyclooxygenase Enzymes in Allergic Inflammation and Asthma. *Prostaglandins Leukot Essent Fatty Acids* 69:157-62.
26. Germolec, DR. 2004. Sensitivity and Predictivity in Immunotoxicity Testing: Immune Endpoints and Disease Resistance. *Toxicol Lett* 149: 109-14.
27. Patterson, RM, DR Germolec. 2005. Toxic Oil Syndrome: Review of Immune Aspects of the Disease. *J. Immunotoxicol.* 2: 1-8. PMID:18958659
28. Selgrade MK, Lemanske RF Jr, Gilmour MI, Neas LM, Ward MD, Henneberger PK, Weissman DN, Hoppin JA, Dietert RR, Sly PD, Geller AM, Enright PL, Backus GS, Bromberg PA, Germolec DR, Yeatts KB, 2006. Induction of asthma and the environment: what we know and need to know. *Environ Health Perspect*, 114:615-9.
29. Luebke, RW, Holsapple MP, Ladics, GS, Luster, MI, Selgrade, MJ, Smialowicz, RJ, Woolhiser, MR, Germolec, DR. 2006. Immunotoxicogenomics: The potential of genomics technology in the immunotoxicity risk assessment process. *Tox Sci*, 94: 22-7.
30. Burns-Naas, LA, Dearman, RJ, Germolec, DR, Kaminski, NE, Kimber, I, Ladics, GS, Luebke, RW, Pfau, JC, Pruetz, SB. 2006. "Omics" Technologies and The Immune System. *Toxicology Mechanisms and Methods* 16:101-19.
31. Carey MA, Card JW, Voltz JW, Germolec DR, Korach KS, Zeldin DC. 2007. The impact of sex and sex hormones on lung physiology and disease: lessons learned from animal studies. *Am J Physiol Lung Cell Mol Physiol* 293:L272-8.
32. Carey MA, Card JW, Voltz JW, Arbes SJ Jr, Germolec DR, Korach KS, Zeldin DC. 2007. It's all about sex: gender, lung development and lung disease. *Trends Endocrinol Metab* 18: 308-13.
33. Germolec DR. 2008. Histological examination of the lymphoid organs is not a sufficiently reliable predictor of immunotoxicity. *Perspectives in Clinical and Experimental Immunotoxicology*.
34. Woodruff TJ, Zeise L, Axelrad DA, Guyton KZ, Janssen S, Miller M, Miller GG, Schwartz JM, Alexeeff G, Anderson H, Birnbaum L, Bois F, Cogliano VJ, Crofton K, Euling SY, Foster PM, Germolec DR, Gray E, Hattis DB, Kyle AD, Luebke RW, Luster MI, Portier C, Rice DC, Solomon G, Vandenberg J, Zoeller RT. 2008. Meeting report: moving upstream-evaluating adverse upstream end points for improved risk assessment and decision-making. *Environ Health Perspect*. 116:1568-75. PMID: 19057713

35. Dobrovolskaia MA, Germolec DR, Weaver JL. 2009. Evaluation of nanoparticle immunotoxicity. *Nat Nanotechnol.* 4:411-4. PMID: 19581891
36. Dietert RR, DeWitt JC, Germolec DR, Zelikoff JT. 2010 Breaking patterns of environmentally influenced disease for health risk reduction: immune perspectives. *Environ Health Perspect.* 118:1091-9. PMID: 20483701
37. Germolec DR, Frawley RP, Evans E. 2010. Markers of inflammation. *Methods Mol Biol.* 2010;598:53-73. PMID:19967506
38. Dietert RR, DeWitt JC, Germolec DR, Zelikoff JT. 2010. Breaking patterns of environmentally influenced disease for health risk reduction: immune perspectives. *Environ Health Perspect.* 2010 118:1091-9.
39. Corsini E, Oukka M, Pieters R, Kerkvliet NI, Ponce R, Germolec DR. 2011. Alterations in regulatory T-cells: rediscovered pathways in immunotoxicology. *J Immunotoxicol.* 8:251-7. PMID: 21848365
40. Dewitt JC, Peden-Adams MM, Keller JM, Germolec DR. 2011. Immunotoxicity of Perfluorinated Compounds: Recent Developments. *Toxicol Pathol.* 2012;40(2):300-11. PMID:22109712
41. Barchowsky A, Buckley LA, Carlson GP, Fitsanakis VA, Ford SM, Genter MB, Germolec DR, Leavens TL, Lehman-McKeeman LD, Safe SH, Sulentic CE, Eidemiller BJ. The Toxicology Education Summit: building the future of toxicology through education. *Toxicol Sci.* 2012 Jun;127(2):331-8. PMID: 22461448
42. Germolec D, Kono DH, Pfau JC, Pollard KM. Animal models used to examine the role of the environment in the development of autoimmune disease: findings from an NIEHS Expert Panel Workshop. *J Autoimmun.* 2012 Dec;39(4):285-93. PMID: 22748431
43. Miller FW, Pollard KM, Parks CG, Germolec DR, Leung PS, Selmi C, Humble MC, Rose NR. Criteria for environmentally associated autoimmune diseases. *J Autoimmun.* 2012 Dec;39(4):253-8. PMID: 22771005
44. Boverhof DR, Ladics G, Luebke B, Botham J, Corsini E, Evans E, Germolec D, Holsapple M, Loveless SE, Lu H, van der Laan JW, White KL Jr, Yang Y. Approaches and considerations for the assessment of immunotoxicity for environmental chemicals: a workshop summary. *Regul Toxicol Pharmacol.* 2014 Feb;68(1):96-107. PMID: 24280359

45. Corsini E, Luebke RW, Germolec DR, Dewitt JC. Perfluorinated compounds: Emerging POPs with potential immunotoxicity. *Toxicol Lett.* 2014 Feb 3. pii: S0378-4274(14)00058-7. PMID: 24503008
46. Parks, CG, Miller FW, Pollard KM, Selmi C, Germolec D, Joyce K, Rose NR, Humble MC. Expert panel workshop consensus statement on the role of the environment in the development of autoimmune disease. 2014. *Int J Mol Sci.* 2014 Aug 15;15(8):14269-97. PMID: 25196523
47. DeWitt JC, Germolec DR, Luebke RW, Johnson VJ. Associating Changes in the Immune System with Clinical Diseases for Interpretation in Risk Assessment. *Curr Protoc Toxicol.* 2016 Feb 1;67:18.1.1-18.1.22. PMID: 26828330
48. Germolec D, Luebke R, Rooney A, Shipkowski K, Vandebriel R, van Loveren H. Immunotoxicology: A brief history, current status and strategies for future immunotoxicity assessment. *Current Opinion in Toxicology.* *Curr Opin Toxicol.* 2017 Aug;5:55-59.
49. Germolec DR, Shipkowski KA, Frawley RP, Evans E. Markers of Inflammation. *Methods Mol Biol.* 2018;1803:57-79. PMID: 29882133

Book Chapters

1. Germolec, DR. 1999. The use of Enzyme-Linked Immunosorbent Assay to Quantitate Proteins in Biological Fluids. In: *Methods in Molecular Medicine/Neurodegeneration*, GJ Harry and H Tilson (eds.) Humana Press, Totowa, NJ, pp 191-200.
2. Selgrade, MJK, Germolec, DR, Luebke, RW, Smialowicz, RJ, Ward, MD, Sailstad, DM. 2001. Immunotoxicity. In *Introduction to Biochemical Toxicology*, 3rd Edition, E. Hodgson, and R.C. Smart, (eds), J. Wiley and Sons, NY, NY, pp 561-597.
3. Luster, MI, Simeonova, PP, Germolec, DR.: Immunotoxicology. 2002. In: *Encyclopedia of Life Sciences Volume 10*, Nature Publishing Group, London, UK, pp 131-136.
4. Luster, MI, LM Blanciforti, DR Germolec, C Parks, M Kashon, R Luebke. 2004. Associating changes in the immune system with clinical diseases for interpretation in risk assessment. In: *Current Protocols in Toxicology*. DA Lawrence et al. (eds.) Wiley and Sons, New York, pp. 18.1-18.20.

5. Germolec, DR. Animal models in the study of Autoimmune Disease. 2005. In: Encyclopedic Reference of Immunotoxicology, H-W Vohr (ed). Springer Verlag, Berlin, pp. 75-79.
6. Luster, MI, DR Germolec, C Parks, L Blanciforti, M Kashon, R Luebke. Are changes in the Immune System predictive of Clinical Disease? 2005. In: Investigative Immunotoxicology. H Tryphonas et al. (eds) Taylor and Francis, Boca Raton, pp 165-182.
7. DR Germolec, RW Luebke, RV House, GJ Rosenthal. 2006. Toxicological Assessment of the Immune System. In: Toxicology Testing Handbook. D Jacobson-Kram, KA Keller (eds). Informa Health Care, New York, pp 391-415.
8. Patterson, RM, K Trouba, DR Germolec. 2007. Immunotoxicology and Inflammatory Mechanism of Arsenic. In: Immunotoxicology and Immunopharmacology. R. Luebke, R. House and I. Kimber (eds) CRC Press, Boca Raton, pp 277-290.
9. Luster, MI, CG Parks, DR Germolec. 2007. Interpreting Immunotoxicology Data for Risk Assessment. In: Immunotoxicology and Immunopharmacology. R. Luebke, R. House and I. Kimber (eds) CRC Press, Boca Raton, pp 35-47.
10. Selgrade, MJK, Germolec, DR, Luebke, RW, Smialowicz, RJ, Ward, MD, Bowman, C. 2008. Immunotoxicity. In: Molecular and Biochemical Toxicology, 4th Edition, E. Hodgson and R.C. Smart, (eds), J. Wiley and Sons, Hoboken, NJ, pp 765-804.
11. Germolec, DR, Burns-Naas, LA, Gerberick, GF, Ladics, GS, Pruett, SB, Ryan, C, Yucesoy, B, RLuebke, RW, 2008. "Omics" Technologies and The Immune System. In: Genomics: Fundamentals and Applications, S Choudhuri, and DB Carlson, (eds) Informa, New York, NY, pp 247-268.
12. Luster, MI, Dietert RR, Germolec DR, Luebke RW, Makris SL. 2008. Children's Environmental Health: Developmental Immunotoxicants. In: Encyclopedia of Environmental Health, B Sonawane and R Brown, (eds). Elsevier, Oxford, UK pp 44-50.
13. Luebke RW, Beamer CA, Bowman C, DeWitt, J, Gowdy K, Johnson VJ, Shepherd DM, Germolec DR. 2009. Immunotoxicology. In: General and Applied Toxicology, 3rd Edition, B Ballantyne, T Marrs and T Syversen (eds). Wiley, West Sussex, UK pp 1561-1584.
14. EHC 240. Principles and methods for the risk assessment of chemicals in food. 2009. WHO. Contributing author (Section 4.6).

15. Germolec DR, Luebke RW, Luster MI. 2010. Immunotoxicity. In: Comprehensive Toxicology, 2nd edition, Volume 3: Toxicology Testing and Evaluation, C McQueen (ed). Elsevier, Oxford, UK, pp 211-224.
16. Weaver JL, McKinnon K, Germolec DR. 2010. Phenotypic analysis using very small volumes of blood. Curr Protoc Cytom. Chapter 6:Unit 6.30. PMID: 20938921
17. Rooney AW, Luebke RW, Selgrade MK, Germolec. 2012. Immunotoxicology and Its Application in Risk Assessment. In. Molecular, Clinical and Environmental Toxicology, Volume 3: Environmental Toxicology. A. Luch (ed.) Springer Basel, p251-288.
18. Luebke RW, DeWitt JC, Germolec DR, Salazar KD and Kerkvliet NI. 2012. Immunomodulation by Persistent Organic Pollutants. In: Dioxins and Health, A Schechter (ed). John Wiley & Sons, Hoboken, NJ pp 171-192.
19. Smith MJ, McLoughlin CE, White KL Jr, Germolec DR. 2013. Animal Models to Monitor Adverse Effects of Nanomaterials on the Immune System. In: Handbook of Immunological Properties of Engineered Nanomaterials, M Dobrovolskaia, S McNeil (eds), World Scientific Publishing, Hackensack, NJ, pp 639-670.
20. Thakur S, Germolec DR, Pfau J. 2013. Animal Models to Study Autoimmune Diseases. In: Encyclopedia of Immunotoxicology, HW Vohr, ed. Springer. Online content accessed July 2, 2014: <http://www.springerreference.com/docs/html/chapterdbid/31852.html>
21. Frawley R, Germolec DR, van Loveren H. 2014. Use of Toxicogenomics in Immunotoxicology. In: Molecular Immunotoxicology, E Corsini and H van Loveren eds. John Wiley & Sons, West Sussex, UK, pp 344.

Reports

Toxicology and carcinogenesis studies of 1-bromopropane (CAS No. 106-94-5) in F344/N rats and B6C3F1 mice (inhalation studies). Natl Toxicol Program Tech Rep Ser. 2011 Aug;(564):1-190.

Luebke, R.W., D.A. Basketter, S. Casati, W. Casey, E. Corsini, D.R. Germolec, C. Helma, R.H.H. Pieters, E. L. Roggen, and H. van Loveren. 2012. Alternative

Methods To Detect and Characterize Immunotoxicants: 2012 Perspective: A Report to the OECD Molecular Screening (Toxicogenomics) Advisory Group.